Figure 6. Val, NOX (knockdown and overexpression), MSCs effects on MAPK signaling pathway in H9c2 cells. (A) Western blot analysis of DOX and Val-treatment on p-p38, p-JNK, p-ERK proteins levels. (B, C) Western blot analysis of NOX2 siRNA and NOX4 siRNA treatment on p-p38, p-JNK, p-ERK proteins levels. (D, E) Western blot analysis of NOX2 plasmid and NOX4 plasmid treatment on p-p38, p-JNK, p-ERK proteins levels. (F) Western blot analysis of MSCs and Val-treatment on p-p38, p-JNK, p-ERK proteins levels. (G) Densitometry analysis of the protein bands of p-p38, p-JNK, p-ERK after Val and DOX treatment. (H, I) Densitometry analysis of the protein bands of p-p38, p-JNK, p-ERK after NOX2 siRNA and NOX4 siRNA treatment. (J, K) Densitometry analysis of the protein bands of p-p38, p-JNK, p-ERK after NOX2 plasmid and NOX4 plasmid treatment. (L) Densitometry analysis of the protein bands of p-p38, p-JNK, p-ERK after MSCs and Val treatment. *P<0.05 vs. Control, Negative siRNA or Empty vector; †P<0.05 vs. Dox or DOX+Negative siRNA or DOX+Empty vector; #P<0.05 vs. DOX+Val or DOX+MSCs. DOX, doxorubicin; Val, valsartan; MSCs, mesenchymal stem cells.